Cantor Fitzgerald reiterated a Hold rating on Hologic HOLX and raised its price target from $20 to $21.
Cantor Fitzgerald commented, “Following the close of Hologic's acquisition of Gen-Probe last week, we are updating our model to reflect the new combined entity. Due to integration challenges and ongoing macro/currency headwinds that put a slight damper on 3Q results, we remain at a HOLD but raise our PT from $20 to $21 (13x FY:2013 EPS).”
Hologic closed at $19.65 on Monday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in